Research programme: vaccines - Capo TherapeuticsAlternative Names: Anti-Aβ vaccine - Capo Therapeutics; Anti-tau vaccine - Capo Therapeutics; Anti-β amyloid vaccine - Capo Therapeutics; AV-1947D; AV-1948D; AV-1949D; AV-1950R; AV-1959D; AV-1959R; AV-1960CP; AV-1980D; AV-1980R; AV-1991CP; AV-1992CP
Latest Information Update: 10 Dec 2016
At a glance
- Originator Flinders University; University of California at Irvine
- Developer Capo Therapeutics
- Class Vaccines
- Mechanism of Action Amyloid beta-protein modulators; Immunostimulants; Tau protein modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease; Parkinson's disease